Lv2
180 积分 2022-12-02 加入
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
12小时前
待确认
Defining intermediate-risk non-muscle-invasive bladder cancer
21天前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
3个月前
已完结
Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis
5个月前
已完结
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
5个月前
已完结
Robotic thymectomy in thymic tumors: a multicenter, nation-wide study
6个月前
已完结
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group
6个月前
已完结
Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: A Randomized Prospective Study in 202 Patients with Superficial Bladder Cancer
6个月前
已完结
The Society of Thoracic Surgeons Expert Consensus Document on the Surgical Management of Thymomas
6个月前
已完结
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
7个月前
已完结
皖公网安备34019202002308
